解锁MYC抑制在神经内分泌恶性肿瘤中的放射增敏潜力
本文综述MYC家族转录因子(c-MYC、N-MYC、L-MYC)过表达通过多种机制促进侵袭性神经内分泌恶性肿瘤的放疗抵抗,同时指出MYC过表达在某些癌细胞中 paradoxically 增强放射敏感性。文章还总结了直接MYC抑制剂的临床前和临床开发阶段,探讨其作为成人和儿童神经内分泌恶性肿瘤放射增敏剂的潜力。
要点
- MYC过表达通过促进肿瘤细胞侵袭、DNA损伤修复、氧化应激管理、促生存自噬等机制介导放疗抵抗。
- MYC过表达在某些癌细胞中可通过驱动促凋亡通路(如活性氧诱导的DNA损伤) paradoxically 增强放射敏感性。
- 直接MYC抑制剂在临床前和临床开发中,可能作为成人和儿童神经内分泌恶性肿瘤的放射增敏剂。
核心结论
- MYC过表达通过多种机制促进神经内分泌恶性肿瘤的放疗抵抗,但也可在某些癌细胞中增强放射敏感性。
- 直接MYC抑制剂作为放射增敏剂在成人和儿童神经内分泌恶性肿瘤中具有潜在应用价值。
研究设计与样本
- 综述性文章,探讨MYC在放疗抵抗中的作用及MYC抑制剂的开发阶段。
主要发现
- MYC过表达通过增加肿瘤细胞侵袭、增强DNA损伤修复和氧化应激管理、促生存自噬、循环肿瘤细胞存活、血管生成、休眠觉醒以及调节慢性炎症和宿主免疫等机制促进放疗抵抗。
- MYC过表达 paradoxically 可通过驱动促凋亡通路(如活性氧诱导的DNA损伤压垮细胞修复机制)增强某些癌细胞的放射敏感性。
临床怎么用
- MYC抑制剂可能作为放射增敏剂用于小细胞肺癌、大细胞神经内分泌肺癌、默克尔细胞癌、神经内分泌分化前列腺癌、神经母细胞瘤、中枢神经系统胚胎性肿瘤和髓母细胞瘤等成人和儿童神经内分泌恶性肿瘤。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The MYC family of transcription factors-comprising c-MYC, N-MYC, and L-MYC-plays a pivotal role in oncogenesis, driving cancer progression and resistance to therapy. While MYC proteins have long been considered challenging drug targets due to their intricate structures, recent advances have led to the development of promising inhibitors. This review explores the role of MYC overexpression in promoting radiation therapy resistance in aggressive neuroendocrine malignancies through multiple mechanisms, including increased tumor cell invasion, enhanced DNA damage repair and oxidative stress management, prosurvival autophagy, survival of circulating tumor cells, angiogenesis, awakening from dormancy, and modulation of chronic inflammation and host immunity. Paradoxically, MYC overexpression can also enhance radiosensitivity in certain cancer cells by driving proapoptotic pathways, such as reactive oxygen species-induced DNA damage that overwhelms cellular repair mechanisms, ultimately leading to cell death. Additionally, we provide a comprehensive summary of direct MYC inhibitors, detailing their current stage of preclinical and clinical development as novel anticancer therapeutics. This review highlights the role of MYC in cancer metastasis and radiation therapy resistance while examining the potential of MYC inhibitors as radiosensitizers in adult and pediatric neuroendocrine malignancies, including small cell lung cancer, large cell neuroendocrine lung cancer, Merkel cell carcinoma, neuroendocrine-differentiated prostate cancer, neuroblastoma, central nervous system embryonal tumors, and medulloblastoma.
引用
- Guo Q, Yang W, Robinson G, et al. Unlocking the Radiosensitizing Potential of MYC Inhibition in Neuroendocrine Malignancies. Int J Radiat Oncol Biol Phys. 2025. PMID: 40354951. doi:10.1016/j.ijrobp.2025.04.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。